NEW YORK (GenomeWeb) – Applied BioCode has submitted a high-volume molecular testing platform and a gastrointestinal panel to the US Food and Drug Administration for 510(k) clearance following recently completed clinical trials, the company announced today.
The firm intends its BioCode MDx-3000 automated PCR-based molecular diagnostic testing system to be used in large hospitals and reference labs.